These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34771650)

  • 1. CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy.
    Michot JM; Mouraud S; Adam J; Lazarovici J; Bigenwald C; Rigaud C; Tselikas L; Dartigues P; Danu A; Bigorgne A; Minard V; Ghez D; Marabelle A; Zitvogel L; Ribrag V
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771650
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
    Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
    Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations.
    Gusak A; Fedorova L; Lepik K; Volkov N; Popova M; Moiseev I; Mikhailova N; Baykov V; Kulagin A
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
    Zhou J; Yu X; Hou L; Zhao J; Zhou F; Chu X; Wu Y; Zhou C; Su C
    Lung Cancer; 2021 Mar; 153():143-149. PubMed ID: 33508527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 9. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.
    Nagasaki J; Togashi Y; Sugawara T; Itami M; Yamauchi N; Yuda J; Sugano M; Ohara Y; Minami Y; Nakamae H; Hino M; Takeuchi M; Nishikawa H
    Blood Adv; 2020 Sep; 4(17):4069-4082. PubMed ID: 32870971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
    Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
    Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
    Wang JJ; Burger P; Taube J; Soni A; Chaichana K; Sheu M; Belcaid Z; Jackson C; Lim M
    Cureus; 2019 Dec; 11(12):e6352. PubMed ID: 31938638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.
    Karihtala K; Leivonen SK; Brück O; Karjalainen-Lindsberg ML; Mustjoki S; Pellinen T; Leppä S
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass cytometry of Hodgkin lymphoma reveals a CD4
    Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
    Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis].
    Liu XY; Yuan XL; Ma RJ; Xu H; Yang SW; Nie L; Zhang L; Hu AX; Li Z; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(36):2846-2853. PubMed ID: 32988145
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
    Phadke MS; Li J; Chen Z; Rodriguez PC; Mandula JK; Karapetyan L; Forsyth PA; Chen YA; Smalley KSM
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 19. Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment.
    Yang M; Du W; Yi L; Wu S; He C; Zhai W; Yue C; Sun R; Menk AV; Delgoffe GM; Jiang J; Lu B
    Oncoimmunology; 2020; 9(1):1708064. PubMed ID: 32076578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1
    Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
    Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.